

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

Diabetes & Metabolic Syndrome: Clinical Research & Reviews

journal homepage: www.elsevier.com/locate/dsx



Letters to the Editor

Care of Parkinson's disease (PD) patients in times of covid-19 pandemic



Keywords:
Parkinson disease
Covid-19
Neuroleptic Malignant Syndrome
Levodopa
Apomorphine pump

Dear editor

Sir, Recently few articles have been published on covid-19 cure with co-morbidities and associated neurological disorder but we want to draw your kind attention towards the continuous less attentiveness towards Parkinson's disease (PD) patients [1]. There have been few cases reported which showed PD can occur even after covid-19 infection [2-5]. PD patients are usually elderly and having multiple co-morbidities like dementia, cerebro-vascular diseases and are at a significant risk of severe covid-19 infection and thus need special attention in home or in hospital. Worsening of PD symptoms occurred in the presence of covid-19 infection probably due to direct neuro-invasion of sars-cov 2 infection in central nervous system causing damage to nigrostriatal dopamine system associated with pharmacodynamic changes and therefore needs additional Levodopa dose [6,7]. Some non-motor symptoms of PD include anosmia, fatigue, and these non-motor symptoms may be delayed to covid-19 confirmation [8]. Home quarantine PD patients may have some problems due to self medication (over-the-counter drug) and drug interaction [9]. Dementia, autonomic symptoms like constipation and urinary problem, sexual dysfunction, orthostatic hypotension may be increased (deterioration) due to antihistamines like diphenhydramine [9]. This deterioration of symptoms probably due to systemic inflammation. Patients with MAO-B inhibitors like Rasagaline, Selegiline, Safinamide may cause drug interaction with drugs containing pseudoephedrine, phenylpropanolamine [10]. MAO-B inhibitors with dexamethasone are not allowed due to the possibility of serotonergic syndrome [11]. MAO-B inhibitors with decongestants may lead to severe hypertension [12]. Advance PD with pulmonary restriction may be due to Levodopa dose (low or excessive) may result in pulmonary decompensation and Pneumonia (respiratory muscle bradykinesia, rigidity, dystonia) which may cause difficulty in intubation, swallowing difficulty may result in aspiration. Some inappropriate omission and commission of anti-PD drug or stress may result in Parkinsonism hyperpyrexia syndrome (Neuroleptic Malignant Syndrome). Rescue drugs like subcutaneous Apomorphine, Apomorphine pump, Levodopa-Carbidopa intestinal gel, transdermal rotigotine patch are not easily available in ICU and hence neurologists are essential for PD patient with covid-19 infection [13]. Amantadine is used as an add-on therapy in this circumstances because it has anti-viral property which block M2 protein receptor and can also block lysosomal gene expression protein [14].

This Covid-19 pandemic transforms the lives of individuals around the globe. So if PD patients are infected there may be many concerns like worsening of symptoms, issue with their self medication and ICU challenges. The role of Amantadine is a very interesting observation and its side effects need further research. Thus, PD patients who are diagnosed with covid-19 infection should need meticulous management.

Financial support and sponsorship

No source of funding.

Declaration of competing interest

There are no conflicts of interests.

References

- [1] Joshi SR. COVID-19 care in India: evolving paradigms from public health to critical care. J Assoc Phys India 2020;68:56–8.
- [2] Cohen, Mikhal E et al. A case of probable Parkinson's disease after SARS-CoV-2 infection, The Lancet Neurology, Volume 19, Issue 10, 804 - 805.
- [3] Nazire Belgin Akilli, Alper Yosunkaya. Part of the Covid 19 puzzle: acute parkinsonism. The American Journal of Emergency Medicine 2021 (ISSN 0735-6757), https://doi.org/10.1016/j.ajem.2021.02.050. In press.
- [4] Faber I, Brandão PR, Menegatti F, de Carvalho Bispo DD, Maluf FB, Cardoso F. Coronavirus disease 2019 and parkinsonism: a non-post-encephalitic case. Mov Disord 2020;35(10):1721–2.
- [5] Makhoul K, Jankovic J. Parkinson's disease after COVID-19. J Neurol Sci 2021;15. 422.
- [6] Fearon C. A. Fasano/COVID-19 and PD. J Parkinsons Dis 2021;11:431-44. https://doi.org/10.3233/JPD-202320.
- [7] Hainque E, Grabli D. Rapid worsening in Parkinson's disease may hide COVID-19 infection. Park Relat Disord 2020;75:126-7. https://doi.org/10.1016/ i.parkreldis.2020.05.008.
- [8] Papa SM, Brundin P, Fung VSC, et al. Impact of the COVID-19 pandemic on Parkinson's disease and movement disorders. Mov Disord Clin Pract 2020;7(4): 357–60. https://doi.org/10.1002/mdc3.12953. Published 2020 Apr 16.
- [9] Elbeddini, et al. Journal of Clinical Movement Disorders 2020;7. https://doi.org/10.1186/s40734-020-00089-4. 7.
- [10] Tan M, Wagner M. Medications to Be avoided or used with caution in Parkinson's disease. Staten Island: American Parkinson Disease Association; 2016.
- [11] Rasagiline. Lexi-drugs online. Hudson. Lexicomp Inc; 2020. Available from: http://online.lexi.com. Subscription required to view, updated 12 June 2020; cited 14 June 2020.
- [12] Phenylephrine (Nasal). Lexi-drugs online. Hudson. Lexicomp Inc; 2020. Available from: http://online.lexi.com. Subscription required to view, updated 28

May 2020; cited 14 June 2020.

- [13] Fasano A, Antonini A, Katzenschlager R, Krack P, Odin P, Evans AH, et al. Management of Advanced Therapies in Parkinson's disease patients in times of humanitarian crisis: the COVID-19 experience. Mov Disord Clin Pract 2020;7(4): 361–72
- [14] Tipton P, Wszolek Z. What can Parkinson's disease teach us about COVID19. Neruologia Neruochirugia Polska 2020;54(2):204–6.

Sidhartha Chattopadhyay^{a,*} ^a Department of Neuromedicine, KPC Medical College & Hospital, Jadavpur, Kolkata, 700032, West Bengal, India * Department of Neuro-medicine, KPC Medical College and Hospital, Jadavpur, Kolkata, West Bengal, India. *E-mail address:* sidharthachatterjee111@gmail.com.

24 May 2021